Online inquiry

IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12853MR)

This product GTTS-WQ12853MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TLR2 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001318787.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7097
UniProt ID O60603
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12853MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9860MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ15195MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ9356MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ6098MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ4668MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986089
GTTS-WQ14403MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ6264MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ4716MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BOS161721
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW